Recent Finacing
Recent Raise
Edgewood Oncology is a clinical-stage biotech developing BTX-A51, a small-molecule inhibitor targeting CK1α, CDK7 and CDK9, conducting Phase 2 trials in AML (azacitidine combo) and planning breast cancer.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Edgewood Oncology.
